Malamo Countouris is a Cardiology physician affiliated with University of Pittsburgh. OpenAlex indexes 88 publications with 571 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Lothrop St
Upmc Montefiore Suite N-715
Pittsburgh, PA 152132536
Telephone
412-692-4700Registry record last updated 25 Mar 2021.
Clinical trials
- Mobile Health Program for Post-Preeclampsia Hypertension
Sponsor: University of Pittsburgh
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20251 payment
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20241 payment
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20233 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
84.8%Statin21.8%Atorvastatin Calcium60%Rosuvastatin Calcium40%Part D≥31 patientsBeta blocker21.4%Carvedilol50%Metoprolol Succinate29%Bisoprolol Fumarate14%Metoprolol Tartrate7%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
8.3%SGLT2 inhibitor5.8%Jardiance72%Farxiga28%Part D<11 patientsPotassium supplement2.4%Potassium Chloride100%Part D<11 patientsBlood & clotting
6.9%Factor Xa inhibitor5.4%Eliquis70%Xarelto30%Part D<11 patientsP2Y12 inhibitor1.5%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Reversing Later Life Left Ventricular Remodeling among Individuals with a History of Preeclampsia and Current Hypertension
University of Pittsburgh at Pittsburgh
FY2026$190,168K23HL179475
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Toren Finkel, MD/PHD
University of Pittsburgh
Sally Wenzel, MD
University of Pittsburgh
Mary Phillips, MD
University of Pittsburgh
Jared Magnani, MD, MSc
University of Pittsburgh
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”